Introduction:
The global market for DTP vaccines is expected to witness significant growth in the coming years, with China emerging as a key player in the industry. With increasing awareness about the importance of vaccination and the rise in government initiatives to promote immunization, the demand for DTP vaccines in China is on the rise. In 2021, China produced over 200 million doses of DTP vaccines, accounting for a significant portion of the global market share.
Top 10 DTP Vaccine Producers in China 2026:
1. Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is a leading pharmaceutical company in China, specializing in the production of vaccines. In 2026, Sinovac Biotech is projected to produce over 50 million doses of DTP vaccines, solidifying its position as the top producer in the country.
2. China National Pharmaceutical Group (Sinopharm)
Sinopharm is a state-owned enterprise in China that plays a crucial role in the production of vaccines. With a production volume of over 40 million doses of DTP vaccines in 2026, Sinopharm is a key player in the market.
3. Beijing Tiantan Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd. is a leading vaccine manufacturer in China, known for its high-quality products. In 2026, the company is expected to produce over 30 million doses of DTP vaccines, catering to the growing demand in the market.
4. Wuhan Institute of Biological Products Co., Ltd.
Wuhan Institute of Biological Products Co., Ltd. is a renowned vaccine producer in China, known for its research and development capabilities. With a production volume of over 25 million doses of DTP vaccines in 2026, the company continues to make significant contributions to the industry.
5. Changchun Institute of Biological Products Co., Ltd.
Changchun Institute of Biological Products Co., Ltd. is a key player in the vaccine market in China, with a focus on innovation and quality. In 2026, the company is projected to produce over 20 million doses of DTP vaccines, meeting the growing demand from both domestic and international markets.
6. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. is a leading biopharmaceutical company in China, with a strong presence in the vaccine industry. With a production volume of over 15 million doses of DTP vaccines in 2026, the company continues to expand its market share and reach.
7. Hualan Biological Engineering Inc.
Hualan Biological Engineering Inc. is a prominent player in the vaccine market in China, known for its cutting-edge research and development efforts. In 2026, the company is expected to produce over 10 million doses of DTP vaccines, contributing to the overall growth of the industry.
8. Shanghai Institute of Biological Products Co., Ltd.
Shanghai Institute of Biological Products Co., Ltd. is a well-established vaccine manufacturer in China, with a strong focus on product quality and safety. With a production volume of over 8 million doses of DTP vaccines in 2026, the company continues to uphold its reputation as a reliable supplier in the market.
9. Liaoning Chengda Biotechnology Co., Ltd.
Liaoning Chengda Biotechnology Co., Ltd. is a rising star in the vaccine industry in China, known for its innovative products and solutions. In 2026, the company is projected to produce over 5 million doses of DTP vaccines, positioning itself as a key player in the market.
10. Shenzhen Kangtai Biological Products Co., Ltd.
Shenzhen Kangtai Biological Products Co., Ltd. is a leading biopharmaceutical company in China, with a strong focus on vaccine production. With a production volume of over 3 million doses of DTP vaccines in 2026, the company continues to expand its market reach and influence.
Insights:
The DTP vaccine market in China is poised for significant growth in the coming years, driven by factors such as increasing government support for immunization programs and rising awareness about the importance of vaccination. With key players like Sinovac Biotech Ltd., Sinopharm, and Beijing Tiantan Biological Products Co., Ltd. leading the way, the industry is set to witness a surge in production volumes and market share. In 2026, the total production of DTP vaccines in China is expected to exceed 200 million doses, highlighting the country’s pivotal role in the global vaccine market. As new technologies and innovations continue to shape the industry landscape, Chinese vaccine producers are well-positioned to capitalize on the growing demand for DTP vaccines both domestically and internationally.
Related Analysis: View Previous Industry Report
